APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1

Experts Video on ILD Management

Document ID: PC-SG-101589

30/06/2022

Author: Boehringer Ingelheim

RELATED CONTENT

 
PC-SG-101589
Production date: June 2022